About Us | Bossun Health

Quality first, Customer first

 

BossunHealth Group was established in 2014, Toronto, Canada. In 2016, BossunHealth Group setup strategic partner relationship with Medidys, the largest private clinic provider, Canada; BossunHealth Group obtained asset injection from Wecare group, Canada

About Us | Bossun Health

About Us | Bossun Health

Quality first, Customer first

 

BossunHealth Group was established in 2014, Toronto, Canada. In 2016, BossunHealth Group setup strategic partner relationship with Medidys, the largest private clinic provider, Canada; BossunHealth Group obtained asset injection from Wecare group, Canada

About Us | Bossun Health

Wide Services

Our group has established a number of offices and service centers across Canada, United States, Switzerland and China.

Cloud biotech

Bossun Health operates a biotechnology company named Cloud biotech which focus on genome studies and providing genetic test to our customer.

Quality first, customer first

Our group will constantly provide “Quality first, Customer first” healthcare services to our potential customers in the future.

Our Story

link

Bossunhealth Group博盛医疗, is a healthcare management group dedicated to providing global medical services, leading medical research, and overseas medical education. Bossunhealth Group was founded in Toronto, the largest city of Canada, in 2014 by a group of researchers, experts, and clinical specialists with long-term work and research experience at well-known global medical and research institutions.

Dr. Wang Qi

Dr. Wang Qi

Founder and CEO

He is currently employed as a research association professor at UHN, University of Toronto.
See More ...
He is the AACR members of the American Cancer Society Dr. Wang graduated from the School of Public Health, Fudan University, received a doctor of medicine; He had work experience in the First Affiliated Hospital of Zhengzhou University, the largest hospital in Asian and Shanghai National Biochip Center, the top gene study company of China. Dr. Wang has more than 10 years of cancer genome experimental experience, focusing on cancer susceptibility research and cancer drug resistance research . Dr. Wang published many highly influential academic research papers in the international academic journals including Carcinogenesis, PlosOne. Dr. Wang is also hired as expert reviewers for SCI academic journals Human & Experimental Toxicology, Biomarkers and Cancer Gene Therapy.
Professor. Wu Fen

Professor. Wu Fen

Director of the Department of Medical

He graduated from New York University Medical Center, USA. She served as laboratory director and senior scientists for more than 10 years.
See More ...
He is the AACR members of the American Cancer Society Dr. Wang graduated from the School of Public Health, Fudan University, received a doctor of medicine; He had work experience in the First Affiliated Hospital of Zhengzhou University, the largest hospital in Asian and Shanghai National Biochip Center, the top gene study company of China. Dr. Wang has more than 10 years of cancer genome experimental experience, focusing on cancer susceptibility research and cancer drug resistance research . Dr. Wang published many highly influential academic research papers in the international academic journals including Carcinogenesis, PlosOne. Dr. Wang is also hired as expert reviewers for SCI academic journals Human & Experimental Toxicology, Biomarkers and Cancer Gene Therapy.
Mr. Jiang Yunfu

Mr. Jiang Yunfu

Director of Marketing Department

He is former Chief Executive Officer of Only Education Group, the largest education group in China which is running by Shanghai Jiaotong University.
See More ...
He is the AACR members of the American Cancer Society Dr. Wang graduated from the School of Public Health, Fudan University, received a doctor of medicine; He had work experience in the First Affiliated Hospital of Zhengzhou University, the largest hospital in Asian and Shanghai National Biochip Center, the top gene study company of China. Dr. Wang has more than 10 years of cancer genome experimental experience, focusing on cancer susceptibility research and cancer drug resistance research . Dr. Wang published many highly influential academic research papers in the international academic journals including Carcinogenesis, PlosOne. Dr. Wang is also hired as expert reviewers for SCI academic journals Human & Experimental Toxicology, Biomarkers and Cancer Gene Therapy.
Mr. Wang

Mr. Wang

The director of business department

He holds a masters degree in business administration from the Open University of Hong Kong.
See More ...
Before joining Shanghai Medicilon Inc. in 2008, Mr. Wang has 9 years of middle and senior level management experience in China Telecom, a large-scale state-owned enterprise, and 6 years of senior management experience in China Unicom, a listed company at home and abroad, as well as 3 years of senior management experience in investment management and health care industry. He served as Deputy General Manager in the municipal branch of China Telecom and China Unicom. He also served as General Manager in a health care investment company. He has rich experience on management and investment.
Laura Artigas

Laura Artigas

The head of technology support

She has a degree in Biotechnology and Biochemistry, MSc in Molecular Biotechnology.
See More ...
Previously she belonged to research team of the Molecular Biology and Biochemistry Research Center for Nanomedicine of Hospital de de la Vall d’ Hebrón de Barcelona, Spain. Laura has broad experience in project management and in transferring biological knowledge to the computational domain (building computable descriptions of available molecular, biochemical, and physiological data).
Dr. Bristow

Dr. Bristow

Research Associate and Participated

He worked at University Maryland Greenebaum Cancer Center in 2011.
See More ...
He worked at University Maryland Greenebaum Cancer Center in 2011 for three months as a research associate and participated in ongoing clinical trials in the field of hematopoietic stem cell transplantation, stem cell biology and transplantation immunology. He currently focuses on biology and immunotherapy of hematologic cancers especially acute myeloid leukemias. Being a clinician, he coordinate clinical/medical aspects of developing and ongoing projects.
Dr. Wang Qi

Dr. Wang Qi

Founder and CEO

He is currently employed as a research association professor at UHN, University of Toronto.

See More..

About Us | Efairs Group

Professor. Wu Fen

Professor. Wu Fen

Director of the Department of Medical

He graduated from New York University Medical Center, USA. She served as laboratory director and senior scientists for more than 10 years.

See More…

About Us | Efairs Group

Mr. Jiang Yunfu

Mr. Jiang Yunfu

Director of Marketing Department

He is former Chief Executive Officer of Only Education Group, the largest education group in China which is running by Shanghai Jiaotong University.

See More…

About Us | Efairs Group

Mr. Wang

Mr. Wang

The director of business department

He holds a masters degree in business administration from the Open University of Hong Kong.

See More..

About Us | Efairs Group

Laura Artigas

Laura Artigas

The head of technology support

She has a degree in Biotechnology and Biochemistry, MSc in Molecular Biotechnology.

See More…

About Us | Efairs Group

Dr. Bristow

Dr. Bristow

Research Associate and Participated

He worked at University Maryland Greenebaum Cancer Center in 2011.

See More…

About Us | Efairs Group

If you are interested in our services then contact our business development team to discuss how we can collaborate.

Dr. Wang Qi, Founder and CEO of Efairs group. He is currently employed as a research association professor at UHN, University of Toronto. He is the AACR members of the American Cancer Society Dr. Wang graduated from the School of Public Health, Fudan University, received a doctor of medicine; He had work experience in the First Affiliated Hospital of Zhengzhou University, the largest hospital in Asian and Shanghai National Biochip Center, the top gene study company of China.

Dr. Wang has more than 10 years of cancer genome experimental experience, focusing on cancer susceptibility research and cancer drug resistance research . Dr. Wang published many highly influential academic research papers in the international academic journals including Carcinogenesis, PlosOne. Dr. Wang is also hired as expert reviewers for SCI academic journals Human & Experimental Toxicology, Biomarkers and Cancer Gene Therapy.

Director of the Department of Medical: Professor. Wu Fen, graduated from New York University Medical Center, USA. She served as laboratory director and senior scientists for more than 10 years.

Professor Wu has more than 30 years of cancer genome experimental and therapy experience. She is very proficient in laboratory testing methods, analytical strategies and therapy design. Professor Wu published more than 50 articles related to clinical research in academic journals including Clinical Cancer Research, Cancer Research, Nature Genetic , Oncology.

Director of Marketing Department: Mr. Jiang Yunfu, former Chief Executive Officer of Only Education Group, the largest education group in China which is running by Shanghai Jiaotong University.

Mr. Jiang is now immigrated to Canada and engaging in investment business. Mr. Jiang has a wealth of domestic business operations, team building and management, business planning and marketing, and a wide range of social networks.

Mr. Wang is the director of business department, He holds a masters degree in business administration from the Open University of Hong Kong. Before joining Shanghai Medicilon Inc. in 2008, Mr. Wang has 9 years of middle and senior level management experience in China Telecom, a large-scale state-owned enterprise, and 6 years of senior management experience in China Unicom, a listed company at home and abroad, as well as 3 years of senior management experience in investment management and health care industry. He served as Deputy General Manager in the municipal branch of China Telecom and China Unicom. He also served as General Manager in a health care investment company. He has rich experience on management and investment.

Laura Artigas is the head of technology support. She has a degree in Biotechnology and Biochemistry, MSc in Molecular Biotechnology. Previously she belonged to research team of the Molecular Biology and Biochemistry Research Center for Nanomedicine of Hospital de de la Vall d' Hebrón de Barcelona, Spain. Laura has broad experience in project management and in transferring biological knowledge to the computational domain (building computable descriptions of available molecular, biochemical, and physiological data).

Dr. Bristow worked at University Maryland Greenebaum Cancer Center in 2011 for three months as a research associate and participated in ongoing clinical trials in the field of hematopoietic stem cell transplantation, stem cell biology and transplantation immunology. He currently focuses on biology and immunotherapy of hematologic cancers especially acute myeloid leukemias. Being a clinician, he coordinate clinical/medical aspects of developing and ongoing projects.